Research & Discovery

Translational Neuropharmacology

Apsynora Biotech is pioneering targeted interventions in brainstem neural circuitry to address chemotherapy-induced nausea and vomiting (CINV). Our lead compound, HT-101, leverages novel mechanisms of action to suppress emetic signaling pathways.

The Mechanism: Modulating Brainstem Emetic Pathways

Chemotherapy-induced emesis is mediated by a complex network involving the Area Postrema (AP), Nucleus Tractus Solitarius (NTS), and the Central Pattern Generator in the medulla oblongata. Standard antiemetics primarily target peripheral 5-HT3 or central NK1 receptors.

HT-101 introduces a differentiated pharmacological approach. By selectively antagonizing novel receptor targets within the dorsal vagal complex, HT-101 interrupts afferent signaling cascades before they propagate to the emetic center, offering profound suppression of both acute and delayed nausea phases.

Pharmacodynamics Summary

adjust Target: Specific G-protein coupled receptors in the AP/NTS.
adjust Affinity (Ki): Sub-nanomolar binding affinity.
adjust Blood-Brain Barrier: Optimized lipophilicity for rapid CNS penetration.

Fig 1. HT-101 Binding Site within the Dorsal Vagal Complex

In Vivo Studies

Preclinical Efficacy Profile

Robust suppression of emetic-like behaviors observed across multiple established preclinical models of CINV.

METHODOLOGY biotech

Acute Phase Suppression

Evaluation of HT-101 vs. Vehicle in reducing immediate onset (0-24hr) emetic episodes following cisplatin administration.

100%

15%

Vehicle HT-101

RESULTS monitoring

Delayed Phase Attenuation

Significant reduction in nausea-like behavior indicators during the difficult-to-treat delayed phase (24-120hr).

24h 120h

SAFETY PROFILE verified_user

Tolerability Margin

Preliminary tox studies indicate a wide therapeutic index with no significant off-target CNS depression or cardiovascular liabilities at therapeutic doses.

NOAEL > 100x ED50

A professional, high-contrast, minimalist photograph of laboratory glassware on a clean white surface.

Strategic Rationale: Polypharmacy in CINV

Despite advances in single-agent antiemetics, highly emetogenic chemotherapy (HEC) regimens often overwhelm solitary pharmacological interventions due to the multi-pathway nature of the emetic reflex.

HT-101 is engineered specifically as a synergistic adjunct. Its unique mechanism of action does not compete with standard 5-HT3 or NK1 receptor antagonists. Instead, it provides a complementary blockade, addressing residual neurotransmitter signaling that current standard-of-care protocols fail to capture.

check
Synergistic Efficacy
check
Non-Overlapping Toxicity
check
Improved Patient Compliance

References & Bibliography

[1]

Hesketh, P. J., et al. (2020). Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 38(24), 2782-2797.

DOI: 10.1200/JCO.20.01296 open_in_new

[2]

Hornby, P. J. (2001). Central neurocircuitry associated with emesis. The American Journal of Medicine, 111(8), 106-112.

DOI: 10.1016/S0002-9343(01)00849-X open_in_new

[3]

World Health Organization. (2023). Essential Medicines for Cancer. Comprehensive guidelines on supportive care and emesis control.

WHO Link open_in_new